Cidara Therapeutics to Present New Data at ASH 2018 Highlighting Potential of Rezafungin to Prevent Invasive Fungal Infection...
November 27 2018 - 8:00AM
Business Wire
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology
company developing novel anti-infectives including immunotherapies,
today announced that the company will present new data highlighting
the potential of rezafungin to prevent invasive fungal infections
in bone marrow transplantation (BMT) patients at the 60th American
Society of Hematology (ASH) Annual Meeting. The 2018 ASH Meeting
will be held December 1-4 in San Diego.
The rezafungin ASH abstract (2071), titled
“Pharmacokinetic-Pharmacodynamic Analyses to Provide Rezafungin
Prophylaxis Dose Selection for Prevention of Invasive Fungal
Infections for Bone Marrow Transplant Patients," will be presented
in a poster session on Saturday, December 1. Fungal infections are
a leading cause of morbidity and mortality among immunocompromised
patients, particularly those undergoing bone marrow
transplantation.
“The data we will present at ASH are important because they
provide further support that a once-weekly dosing regimen of
rezafungin can help to prevent life-threatening fungal infections
in high-risk patients,” said Jeffrey Stein, Ph.D., president and
chief executive officer of Cidara. “We believe rezafungin can
address this serious unmet medical need in immunocompromised
patients and has the potential to be the only single agent approved
to prevent infections caused by common fungal pathogens in bone
marrow transplant patients.”
Rezafungin is a novel antifungal echinocandin being developed as
a once-weekly therapy for the treatment and prevention of serious
invasive fungal infections. Rezafungin is being developed to
address unmet needs in the treatment of candidemia and invasive
candidiasis as well as for prophylaxis of invasive fungal
infections due to the common fungal pathogens Candida, Aspergillus
and Pneumocystis. Cidara plans to start the Phase 3 ReSPECT
prophylaxis clinical trial of rezafungin in patients undergoing
allogeneic bone marrow transplantation in the first quarter of
2019.
About Invasive Fungal Infections
Approximately 97,000 Americans die from hospital-related
invasive fungal infections each year and 90 percent of these
infections are caused by two common fungi, Candida and Aspergillus.
Pneumocystis Pneumonia (PCP) is another serious fungal infection
that commonly afflicts people with weakened immune systems.
Systemic fungal infections typically affect patients whose immune
systems have been compromised, such as patients undergoing organ or
bone marrow transplantation or chemotherapy, including patients
with hematologic malignancies, or patients in intensive care units
and those with prolonged hospital stays.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on
developing new anti-infectives that have the potential to transform
the standard of care and save or improve patients’ lives. The
company is currently advancing its novel echinocandin antifungal,
rezafungin acetate, in a Phase 3 clinical trial in the treatment of
candidemia and invasive candidiasis and plans to initiate a second
Phase 3 trial in the prophylaxis of invasive fungal infections.
Rezafungin has improved pharmacokinetics compared to existing
echinocandins and the potential for expanded utility across patient
settings. It is the only once-weekly product candidate in
development for the treatment and prevention of life-threatening
invasive fungal infections. Cidara also is leveraging its novel
Cloudbreak™ platform to develop antibody-drug conjugates for the
treatment of serious viral and Gram-negative bacterial infections.
Cloudbreak is the first immunotherapy discovery platform designed
specifically to create compounds that directly kill pathogens and
also direct a patient’s immune cells to attack and eliminate
bacterial, fungal or viral pathogens. Cidara is headquartered in
San Diego, California. For more information, please visit
www.cidara.com.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the potential for rezafungin to be a novel treatment and
prophylactic agent against deadly invasive fungal infections,
statements regarding the potential for expanded utility across
patient settings, such as immunocompromised patients, as well as
statements regarding rezafungin’s ability to mitigate the
challenges typically associated with prophylaxis of invasive fungal
infections in immunocompromised and bone marrow transplant
patients, and statements regarding the time of initiation of
rezafungin Phase 3 pivotal trials. Risks that contribute to the
uncertain nature of the forward-looking statements include: the
success and timing of Cidara’s preclinical studies and clinical
trials; regulatory developments in the United States and foreign
countries; changes in Cidara’s plans to develop and commercialize
its product candidates; Cidara’s ability to obtain additional
financing; Cidara’s ability to obtain and maintain intellectual
property protection for its product candidates; and the loss of key
scientific or management personnel. These and other risks and
uncertainties are described more fully in Cidara’s Form 10-Q most
recently filed with the United States Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made. Cidara
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181127005460/en/
INVESTOR CONTACT:Robert H. UhlWestwicke Partners,
LLCManaging Director(858) 356-5932robert.uhl@westwicke.com
MEDIA CONTACT:Christy CurranSam Brown
Inc.615-414-8668ChristyCurran@sambrown.com
Cidara Therapeutics (NASDAQ:CDTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cidara Therapeutics (NASDAQ:CDTX)
Historical Stock Chart
From Sep 2023 to Sep 2024